Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03731715 · ClinicalTrials.gov registry record · Phase 1
Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
A Phase 1 study, sponsored by SK Life Science.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03731715 is a Phase 1 study that has completed, run by SK Life Science. The registered enrollment target is 18 participants.
The verdict
NCT03731715, a Phase 1 study, has completed, sponsored by SK Life Science.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is an open-label, multi-center study of carisbamate in adult and pediatric subjects with LGS, with single- and multiple-dose PK assessments from Days 1 through 73. There will be a Screening Period of up to 28 days and a Treatment Period of 87 days.
Interventions
- DRUG Carisbamate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2022-06-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03731715
The ClinicalTrials.gov registry entry for NCT03731715 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SK Life Science, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Carisbamate is the first listed.
NCT03731715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03731715 about?
NCT03731715 is a clinical study titled "Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome". This is an open-label, multi-center study of carisbamate in adult and pediatric subjects with LGS, with single- and multiple-dose PK assessments from Days 1 through 73. There will be a Screening Period of up to 28 days and a Treatment Period of 87 days.
What is the current status of trial NCT03731715?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2019-02-07. Estimated completion is 2022-06-29.
What interventions are being tested in trial NCT03731715?
The interventions under investigation include: Carisbamate (DRUG).
Who is sponsoring clinical trial NCT03731715?
This trial is sponsored by SK Life Science, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.